Skip to content

GRCE

Grace Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.88
−0.53%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 12, 2026
EPS estimate
-$0.15
Revenue estimate
$1.0M

Latest reported

Last report date
Aug 13, 2026
EPS actual
-$0.91
EPS estimate
-$0.13
Revenue actual
—
Revenue estimate
$400.0K

Track record

Trailing twelve quarters

EPS beats (12Q)
4
EPS misses (12Q)
7
EPS in line (12Q)
1
Avg surprise (4Q)
-153.4%
Revenue beats (12Q)
—
Earnings call history

No earnings call summaries available

Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Aug 13, 2026-$0.13-$0.91Miss -603.79%—
Jun 18, 2026-$0.24-$0.07Beat 70.83%—
Feb 12, 2026-$0.09-$0.14Miss -55.56%—
Nov 13, 2025-$0.12-$0.15Miss -25.00%—
Aug 12, 2025-$0.22-$0.21Beat 4.55%—
Jun 23, 2025-$0.20-$0.21Miss -5.00%—
Feb 13, 2025-$0.24-$0.26Miss -8.33%—
Nov 13, 2024-$0.33-$0.33In line—
Aug 9, 2024-$0.28-$0.24Beat 14.29%—
Jun 21, 2024-$0.35-$0.18Beat 48.57%—
Feb 12, 2024-$0.23-$0.24Miss -4.44%—
Nov 13, 2023-$0.26-$0.32Miss -23.05%—

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026